Navigation Links
CardioDynamics Reports First Quarter 2009 Results
Date:4/9/2009

SAN DIEGO, April 9 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of Impedance Cardiography (ICG) technology, today reported financial results for fiscal first quarter 2009.

Financial Highlights of First Quarter 2009 Compared with First Quarter 2008

  • Net sales of $5.1 million, a 12% decrease from $5.8 million, but a 3% increase excluding large Eastern European hospital group sales in the first quarters of 2008 and 2009
  • ICG sensor revenue increased 12% to $1.7 million, representing 33% of net sales, up from $1.5 million, or 26% of sales
  • Gross margin as a percentage of net sales improved from 69% to 73%
  • Reduced operating expenses by 2% to $4.8 million
  • Operating loss was $1.0 million, which included $202,000 of non-cash charges for depreciation, amortization and equity compensation
  • Net loss from continuing operations of $1.5 million ($0.20 per share loss), down 10% from $1.6 million ($0.23 per share loss)

Additional Key Operating Metrics for the First Quarter of 2009

  • BioZ(R) system sales grew 12% to 76 units, compared to 68 units
  • ICG device sales totaled 158 units bringing the cumulative total sold to over 8,900 ICG monitors and modules, up 11% from 8,000 one year ago
  • U.S. direct sales grew 19% to $3.9 million, up from $3.3 million
  • Field headcount averaged 72 field associates, up from 70 one year ago
  • Investors retained $5.25 million investment in Company's 8% convertible notes

First Quarter 2009 Operating Results Discussion

The Company reported net sales of $5.1 million, a 12% decrease from $5.8 million, but a 3% increase excluding large Eastern European hospital group sales through the Medis subsidiary in both first quarters 2008 and 2009. The decrease in sales growth related to the Eastern European hospital group was offset by 19% growth in U.S. direct sales which included a 12% increase in sensor sales. ICG device sales of 158 units included 25 ICG Modules, 133 ICG monitors, 68 of which were BioZ Dx(R) systems, 8 BioZ(R) Monitors, and 57 Medis ICG monitors.

Overall gross margin percentage improved 4% to 73%, largely due to the non-cash provision of $313,000 of additional reserve for excess, slow moving or obsolete inventory in the first quarter 2008 that did not re-occur in the first quarter, 2009. The additional reserve in first quarter 2008 was primarily driven by lower projected sales of the older model BioZ(R) monitors and the success of the BioZ(R) trade-up program.

A 2% reduction in operating expenses was achieved through a 4% decrease in sales and marketing expenditures, partially offset by a 26% increased investment in research and development during the period. Despite improved gross margins and reduced operating expenses, lower consolidated revenue resulted in an operating loss increase to $1.0 million, from $0.9 million in the same period in 2008. Net loss from continuing operations improved by 10% to $1.5 million or ($0.20) per diluted share.

CEO Comments and Outlook

"We were encouraged by continued growth in the business excluding the large international opportunity that we recorded in first quarter, 2008," stated Michael K. Perry, Chief Executive Officer of CardioDynamics. "We were particularly pleased with the increased growth in our sensor business which was up 12% during the quarter. This was the second consecutive quarter of double-digit sensor revenue growth, the first time since 2007, and is a testament to the success of our newly implemented Comprehensive Customer Care (C3), and BioZ(R) ICG CERTIFIED programs."

Perry continued, "We continue to be optimistic regarding the remainder of the year, but temper our projections given the global economic challenges, tight credit conditions and low consumer confidence which all have an impact on physician buying patterns. In an effort to augment overall revenue growth, we launched a pilot sales program for a new partner product midway through the quarter with a small group of our sales team. We will evaluate the progress in the pilot program during the second quarter to decide whether to introduce the product to the entire sales force during the second half of 2009."

Conference Call Information

Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief Financial Officer, will host a summary of CardioDynamics' first quarter 2009 results in a conference call today, Thursday, April 9, 2009, at 4:30 p.m. (EDT). To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for one month following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed through the Investor Relations section of the Company's website at www.cdic.com or at:

http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=86923&eventID=2141110

About CardioDynamics

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called Impedance Cardiography (ICG). The Company develops, manufactures and markets noninvasive ICG diagnostic and monitoring devices and markets proprietary ICG sensors. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. For additional information, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as the continued success of our C3 and BioZ Certified programs, the accuracy of which is necessarily subject to uncertainties and risks including the Company's primary dependence on the BioZ product line, and various uncertainties characteristic of early stage growth companies, as well as other risks detailed in the Company's filings with the SEC, including its 2008 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.


                  CardioDynamics International Corporation
               In thousands, except per share data (unaudited)

    Selected Consolidated Operational Results      Three Months Ended
                                               February 28,    February 29,
                                                   2009           2008
    Net sales                                    $5,072          $5,762
    Cost of sales                                 1,355           1,775
    Gross margin                                  3,717           3,987
    Research and development                        395             314
    Selling and marketing                         3,570           3,722
    General and administrative                      773             771
    Amortization of intangible assets                26              32
    Loss from operations                         (1,047)           (852)
    Other expense, net                             (225)           (166)
    Loss before income taxes and minority
     interest                                    (1,272)         (1,018)
    Minority interest in income of
     subsidiary                                     (49)           (134)
    Income tax provision                           (139)           (463)
    Income from discontinued operations               -             127
    Net loss                                    $(1,460)        $(1,488)
    Net loss per common share:
      Basic and diluted                          $(0.20)         $(0.21)
    Weighted-average shares used in per
     share calculation:
      Basic and diluted                           7,295           7,107


    Selected Consolidated Balance Sheet Data   February 28,    November 30,
                                                   2009            2008
    Cash and cash equivalents                    $4,562          $6,306
    Accounts receivable, net                      3,734           3,918
    Inventory, net                                1,558           1,490
    Total current assets                         10,299          12,138
    Long-term assets                              3,382           3,428
    Total assets                                 13,681          15,566
    Total current liabilities                     3,862           4,499
    Long-term liabilities                         4,625           4,504
    Total liabilities                             8,487           9,003
    Minority interest                               473             472
    Shareholders' equity                          4,721           6,091


'/>"/>
SOURCE CardioDynamics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Reports Eighth Consecutive Quarterly Revenue Increase Over Prior Year and 12% Revenue Growth in 2008
2. CardioDynamics Announces Investors Retain $5.25 Million 8% Convertible Debt Securities
3. CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008
4. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
5. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
6. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
7. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
8. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
9. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
10. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
11. Streamline Health Solutions, Inc. Reports Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel therapy ... MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason ... extensive financial and operational leadership experience to Advanced Inc. He began his career in ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Hour Power of Water, Global Climate Change and Your Health radio program syndicated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 ... Awards Committee honored excellence in research, development and innovation ... The gala dinner was held in the presence of ... the Russian Federation , Natalia Sanina, ... Mikhail Murashko , Head of Roszdravnadzor, National Service ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... Dec. 2, 2016 Boston Scientific Corporation (NYSE: ... to acquire certain manufacturing assets and capabilities of the ... advanced biological tissue business, as well as a 15% ... million in cash. The Neovasc advanced biological tissue business ... Boston Scientific Lotus™ Valve System. * Upon completion ...
Breaking Medicine Technology: